Indeed, RAF inhibitors (RAFi) combined with MEK blockers have been taken as an FDA-approved therapeutic strategy for numerous RAF-mutant cancers, including melanoma, non-small cell lung carcinoma, and thyroid cancer63. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.